Vemurafenib (ZelborafTM, Roche Pharmaceuticals Ltd, Sydney, Australia), is a serine-threonine kinase BRAF inhibitor that has demonstrated efficacy in treating metastatic or unresectable metastatic melanoma that has a known mutation in BRAF protein [1]. This evidence concerns the gene MARK2 and metastatic melanoma.